V
Valo Therapeutics
Biotech & Life Sciences · Helsinki, Finland · Founded 2016
An immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines MoreLess
Valo Therapeutics is a clinical-stage biotechnology company developing novel oncolytic virus-based cancer immunotherapies.
The company's main platform, PeptiCRAd, is a first-in-class cancer immunotherapy that combines an oncolytic adenovirus with peptide antigens to create a therapeutic vaccine. This approach turns the tumor into an in-situ vaccine, activating the immune system to recognize and destroy cancer cells. The platform is designed to be adaptable, allowing for the use of different tumor-specific peptides to target various types of cancer.
Valo Therapeutics is currently in Phase 1 clinical trials for its lead candidate, PeptiCRAd-1, for the treatment of solid tumors. The company is also developing a pipeline of other PeptiCRAd candidates for different cancer indications and infectious diseases.
Valo Therapeutics' business model is focused on the development and commercialization of its proprietary immunotherapy platforms. The company collaborates with other biotechnology and pharmaceutical companies to advance the development of its product candidates. Valo Therapeutics operates in the cancer immunotherapy market, a rapidly growing segment of the pharmaceutical industry.
Keywords: immunotherapy, oncolytic virus, cancer, vaccine, clinical-stage, biotechnology, PeptiCRAd, solid tumors, infectious diseases, T-cell
Company overview
Valo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Helsinki, Finland
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 62.2
- Investment activity
- 1 companies · latest Aug 2023
- Capital deployed
- —
- Preferred round
- POST IPO CONVERTIBLE
Valuation & funding
Valo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2025 | $21M | $84M | CDP Venture Capital · Fondazione ENEA Tech · Indaco Venture Partners | ↗ |
| EARLY VC✓Equity / VC | Nov 2021 | $12M | $48M | Freeman Road · Mmj Group Holdings | ↗ |
| SEED✓Equity / VC | Feb 2020 | $1.2M | $17M | Undisclosed | — |
| DEBTDebt | Jul 2017 | $4.6M | — | Undisclosed | — |
| SEED✓Equity / VC | Jan 2017 | $3.4M | $14M | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2016 | University of Helsinki | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Valo Therapeutics website traffic
Latest recorded traffic for Valo Therapeutics is 1.1K monthly website visits, up 34.1% over the last three months. Valo Therapeutics's team declined 38.9% over the past year.
Comparisons
Valo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Valo Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Valo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Valo Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Valo Therapeutics has talent and traffic
team presence
In the news
Latest news about Valo Therapeutics
Recent press, funding announcements, and product moves mentioning Valo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Valo Therapeutics
An AI-synthesized read of the highest-engagement posts about Valo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Valo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.